Oral Solid Medications
OVERVIEW
Full Tech Transfer and localization of oral solid medications which cover mainly the chronic diseases (diabetes, hyperlipidemia, cardiovascular. Etc…).
Opportunity Highlights
- Expected Investment size of USD 3.5 Billion for the whole segment and not capex / plant- (capex/ plant is 75 Million)
- Plant capacity: Subjected to review ktpa
- Expected IRR: - Subjected to review %
- Payback period: Subjected to review years
- Job Creation: 588 till 2035 (Source NIS)
- GDP Impact: Subjected to review %
contact our Oral Solid Medications Expert
Thank you for your interest in the Invest Saudi.
We received your inquiry, and we will get back to you shortly.
